etherdesign
Bluelighter
The Drug Enforcement Administration (DEA) today commended House and Senate negotiators for agreeing on legislation to control 26 synthetic drugs under the Controlled Substances Act. These drugs include those commonly found in products marketed as “K2” and “Spice.”
The addition of these chemicals to Schedule I of the Controlled Substances Act will be included as part of S. 3187, the Food and Drug Administration Safety and Innovation Act. Schedule I substances are those with a high potential for abuse; have no medical use in treatment in the United States; and lack an accepted safety for use of the drug.
In addition to scheduling the 26 drugs, the new law would double the length of time a substance may be temporarily placed in schedule I (from 18 to 36 months). In addition to explicitly naming 26 substances, the legislation creates a new definition for “cannabamimetic agents,” creating criteria by which similar chemical compounds are controlled.
In recent years, a growing number of dangerous products have been introduced into the U.S. marketplace. Products labeled as “herbal incense” have become especially popular, especially among teens and young adults. These products consist of plant material laced with synthetic cannabinoids which, when smoked, mimic the delirious effects of THC, the psychoactive ingredient of marijuana. According to the United Nations Office on Drugs and Crime, more than 100 such substances have been synthesized and identified to date. DEA has used its emergency scheduling authority to place in schedule I several of these harmful chemicals.
Newly developed drugs, particularly from the “2C family” (dimethoxyphenethylamines), are generally referred to as synthetic psychedelic/hallucinogens. 2C-E caused the recent death of a 19 year-old in Minnesota.
The substances added to Schedule I of the Controlled Substances Act also include 9 different 2C chemicals, and 15 different synthetic cannabanoids.
The American Association of Poison Control Centers reported that they received 6,959 calls related to synthetic marijuana in 2011, up from 2,906 in 2010.
http://www.justice.gov/dea/pubs/pressrel/pr061912.html
LIST OF CONTROLLED SUBSTANCES
SEC. 1142. ADDITION OF SYNTHETIC DRUGS TO SCHEDULE I OF THE CONTROLLED SUBSTANCES ACT.
(a) Cannabimimetic Agents.–Schedule I, as set forth in section 202(c) of the Controlled Substances Act (21 U.S.C. 812(c)) is amended by adding at the end the following:
“(d)(1) Unless specifically exempted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of cannabimimetic agents, or which contains their salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation.
“(2) In paragraph (1):
“(A) The term `cannabimimetic agents’ means any substance that is a cannabinoid receptor type 1 (CB1 receptor) agonist as demonstrated by binding studies and functional assays within any of the following structural classes:
“(i) 2-(3-hydroxycyclohexyl)phenol with substitution at the 5-position of the phenolic ring by alkyl or alkenyl, whether or not substituted on the cyclohexyl ring to any extent.
“(ii) 3-(1-naphthoyl)indole or 3-(1-naphthylmethane)indole by substitution at the nitrogen atom of the indole ring, whether or not further substituted on the indole ring to any extent, whether or not substituted on the naphthoyl or naphthyl ring to any extent.
“(iii) 3-(1-naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring, whether or not further substituted in the pyrrole ring to any extent, whether or not substituted on the naphthoyl ring to any extent.
“(iv) 1-(1-naphthylmethylene)indene by substitution of the 3-position of the indene ring, whether or not further substituted in the indene ring to any extent, whether or not substituted on the naphthyl ring to any extent.
“(v) 3-phenylacetylindole or 3-benzoylindole by substitution at the nitrogen atom of the indole ring, whether or not further substituted in the indole ring to any extent, whether or not substituted on the phenyl ring to any extent.
“(B) Such term includes–
“(i) 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (CP 47,497);
“(ii) 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (cannabicyclohexanol or CP 47,497 C8-homolog);
“(iii) 1-pentyl-3-(1-naphthoyl)indole (JWH 018 and AM678);
“(iv) 1-butyl-3-(1-naphthoyl)indole (JWH 073);
“(v) 1-hexyl-3-(1-naphthoyl)indole (JWH 019);
“(vi) 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH 200);
“(vii) 1-pentyl-3-(2-methoxyphenylacetyl)indole (JWH 250);
“(viii) 1-pentyl-3-[1-(4-methoxynaphthoyl)]indole (JWH 081);
“(ix) 1-pentyl-3-(4-methyl-1-naphthoyl)indole (JWH 122);
“(x) 1-pentyl-3-(4-chloro-1-naphthoyl)indole (JWH 398);
“(xi) 1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM2201);
“(xii) 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (AM694);
“(xiii) 1-pentyl-3-[(4-methoxy)-benzoyl]indole (SR 19 and RCS 4);
“(xiv) 1-cyclohexylethyl-3-(2-methoxyphenylacetyl)indole (SR 18 and RCS 8); and
“(xv) 1-pentyl-3-(2-chlorophenylacetyl)indole (JWH 203).”.
(b) Other Drugs.–Schedule I of section 202(c) of the Controlled Substances Act (21 U.S.C. 812(c)) is amended in subsection (c) by adding at the end the following:
“(18) 4-methylmethcathinone (Mephedrone).
“(19) 3,4-methylenedioxypyrovalerone (MDPV).
“(20) 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C E).
“(21) 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C D).
“(22) 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C C).
“(23) 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C I).
“(24) 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C T 2).
“(25) 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C T 4).
“(26) 2-(2,5-Dimethoxyphenyl)ethanamine (2C H).
“(27) 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C N).
“(28) 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C P).”.
The addition of these chemicals to Schedule I of the Controlled Substances Act will be included as part of S. 3187, the Food and Drug Administration Safety and Innovation Act. Schedule I substances are those with a high potential for abuse; have no medical use in treatment in the United States; and lack an accepted safety for use of the drug.
In addition to scheduling the 26 drugs, the new law would double the length of time a substance may be temporarily placed in schedule I (from 18 to 36 months). In addition to explicitly naming 26 substances, the legislation creates a new definition for “cannabamimetic agents,” creating criteria by which similar chemical compounds are controlled.
In recent years, a growing number of dangerous products have been introduced into the U.S. marketplace. Products labeled as “herbal incense” have become especially popular, especially among teens and young adults. These products consist of plant material laced with synthetic cannabinoids which, when smoked, mimic the delirious effects of THC, the psychoactive ingredient of marijuana. According to the United Nations Office on Drugs and Crime, more than 100 such substances have been synthesized and identified to date. DEA has used its emergency scheduling authority to place in schedule I several of these harmful chemicals.
Newly developed drugs, particularly from the “2C family” (dimethoxyphenethylamines), are generally referred to as synthetic psychedelic/hallucinogens. 2C-E caused the recent death of a 19 year-old in Minnesota.
The substances added to Schedule I of the Controlled Substances Act also include 9 different 2C chemicals, and 15 different synthetic cannabanoids.
The American Association of Poison Control Centers reported that they received 6,959 calls related to synthetic marijuana in 2011, up from 2,906 in 2010.
http://www.justice.gov/dea/pubs/pressrel/pr061912.html
LIST OF CONTROLLED SUBSTANCES
SEC. 1142. ADDITION OF SYNTHETIC DRUGS TO SCHEDULE I OF THE CONTROLLED SUBSTANCES ACT.
(a) Cannabimimetic Agents.–Schedule I, as set forth in section 202(c) of the Controlled Substances Act (21 U.S.C. 812(c)) is amended by adding at the end the following:
“(d)(1) Unless specifically exempted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of cannabimimetic agents, or which contains their salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation.
“(2) In paragraph (1):
“(A) The term `cannabimimetic agents’ means any substance that is a cannabinoid receptor type 1 (CB1 receptor) agonist as demonstrated by binding studies and functional assays within any of the following structural classes:
“(i) 2-(3-hydroxycyclohexyl)phenol with substitution at the 5-position of the phenolic ring by alkyl or alkenyl, whether or not substituted on the cyclohexyl ring to any extent.
“(ii) 3-(1-naphthoyl)indole or 3-(1-naphthylmethane)indole by substitution at the nitrogen atom of the indole ring, whether or not further substituted on the indole ring to any extent, whether or not substituted on the naphthoyl or naphthyl ring to any extent.
“(iii) 3-(1-naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring, whether or not further substituted in the pyrrole ring to any extent, whether or not substituted on the naphthoyl ring to any extent.
“(iv) 1-(1-naphthylmethylene)indene by substitution of the 3-position of the indene ring, whether or not further substituted in the indene ring to any extent, whether or not substituted on the naphthyl ring to any extent.
“(v) 3-phenylacetylindole or 3-benzoylindole by substitution at the nitrogen atom of the indole ring, whether or not further substituted in the indole ring to any extent, whether or not substituted on the phenyl ring to any extent.
“(B) Such term includes–
“(i) 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (CP 47,497);
“(ii) 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (cannabicyclohexanol or CP 47,497 C8-homolog);
“(iii) 1-pentyl-3-(1-naphthoyl)indole (JWH 018 and AM678);
“(iv) 1-butyl-3-(1-naphthoyl)indole (JWH 073);
“(v) 1-hexyl-3-(1-naphthoyl)indole (JWH 019);
“(vi) 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH 200);
“(vii) 1-pentyl-3-(2-methoxyphenylacetyl)indole (JWH 250);
“(viii) 1-pentyl-3-[1-(4-methoxynaphthoyl)]indole (JWH 081);
“(ix) 1-pentyl-3-(4-methyl-1-naphthoyl)indole (JWH 122);
“(x) 1-pentyl-3-(4-chloro-1-naphthoyl)indole (JWH 398);
“(xi) 1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM2201);
“(xii) 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (AM694);
“(xiii) 1-pentyl-3-[(4-methoxy)-benzoyl]indole (SR 19 and RCS 4);
“(xiv) 1-cyclohexylethyl-3-(2-methoxyphenylacetyl)indole (SR 18 and RCS 8); and
“(xv) 1-pentyl-3-(2-chlorophenylacetyl)indole (JWH 203).”.
(b) Other Drugs.–Schedule I of section 202(c) of the Controlled Substances Act (21 U.S.C. 812(c)) is amended in subsection (c) by adding at the end the following:
“(18) 4-methylmethcathinone (Mephedrone).
“(19) 3,4-methylenedioxypyrovalerone (MDPV).
“(20) 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C E).
“(21) 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C D).
“(22) 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C C).
“(23) 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C I).
“(24) 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C T 2).
“(25) 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C T 4).
“(26) 2-(2,5-Dimethoxyphenyl)ethanamine (2C H).
“(27) 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C N).
“(28) 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C P).”.
Last edited:
. Oh well, back to the old illegal shit.
